MedDataX Logo

Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients

NCT ID: NCT01177267

Last Updated: 2012-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using a retrospective database analysis, OA patients taking at least one CYP450-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxycodone, or tramadol) and at least one other prescription drug metabolized via the CYP450 system were evaluated for an incident drug-drug exposure (DDE), which places them at risk for experiencing a pharmacokinetic drug-drug interaction (DDI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids

NCT01177241

Chronic Low Back Pain
COMPLETED

Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol

NCT04249674

Interaction Pain
UNKNOWN

Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac

NCT03766984

Pharmacokinetics
COMPLETED PHASE1

A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip

NCT00325858

Chronic Pain
COMPLETED PHASE3

A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up

NCT00912015

Pain Osteoarthritis, Knee
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* osteoarthritis

Exclusion Criteria

* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NEMA Research, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joseph Pergolizzi, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph Pergolizzi, MD

Role: PRINCIPAL_INVESTIGATOR

NEMA Research

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CYP450OA3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers
NCT03312777 COMPLETED PHASE1
Genetics of Cytochrome CYP2D6 and Effects of Codeine and Tramadol on Postoperative Pain Management
NCT06723379 COMPLETED
Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients
NCT01517295 COMPLETED PHASE4
Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers
NCT01443520 COMPLETED PHASE4
Use of Driving Tests to Evaluate Patient Performance on Oral Opioids
NCT00659035 ACTIVE_NOT_RECRUITING
Omnitram Pharmacokinetic Study In Healthy Volunteers
NCT02205554 COMPLETED PHASE1
AZD2066 Cocktail Study
NCT00930306 COMPLETED PHASE1
A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day
NCT00952068 COMPLETED PHASE2
Dronabinol On the Pain Experience
NCT05820685 TERMINATED PHASE4
The Effects of Minocycline in Opioid-maintained Patients
NCT02359006 COMPLETED NA
Effects of Opioids and NSAIDs on Sympathetic Nervous System and Vascular Function
NCT03781544 RECRUITING PHASE4
Opioid and Cannabinoid Pharmacokinetic Interactions
NCT00308555 COMPLETED PHASE1
Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
NCT03411759 COMPLETED
An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee
NCT00833911 COMPLETED PHASE3
Characterization of the Iatrogenic Drug Risk in Elderly Patients With Chronic Pain Who Consult the Pain Assessment and Treatment Centre at the Nimes University Hospital
NCT04006444 COMPLETED
Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
NCT02932579 TERMINATED PHASE4
PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects
NCT02329561 COMPLETED PHASE1
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
NCT00225797 COMPLETED PHASE3
Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany
NCT03778450 COMPLETED
A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee
NCT00950651 COMPLETED PHASE3
Influence of Diabetes on Tramadol Pharmacokinetics
NCT02246712 COMPLETED PHASE4
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
NCT03947749 COMPLETED
Usage and Plan of Care Changes Due to Drug Screenings
NCT02995278 UNKNOWN
Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
NCT02117583 COMPLETED PHASE1
An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg
NCT00399295 COMPLETED PHASE1